Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09ETH
|
|||
| Former ID |
DIB016237
|
|||
| Drug Name |
E-7050
|
|||
| Synonyms |
C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42] | Phase 1 | [1], [2] | |
| Company |
Eisai Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H37F2N7O4
|
|||
| Canonical SMILES |
CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(=C3)OC4=CC(=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
|
|||
| InChI |
1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)
|
|||
| InChIKey |
UQRCJCNVNUFYDX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 928037-13-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
24765550, 28721555, 40652761, 141053681, 152258444, 160644595, 160647280, 162009761, 162011993, 162108794, 163312255, 164045124, 172918939, 174525694, 174531528, 185990484, 198990522, 223388544, 224233676, 225848215, 227908873, 247721050, 249565639, 249814484, 252160604, 252441725, 252451558, 252553660
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7956). | |||
| REF 2 | ClinicalTrials.gov (NCT02533102) Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers. | |||
| REF 3 | E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.